{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:50:28Z","timestamp":1789645828533,"version":"4.0.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.eprac.2023.09.011","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:16:35Z","timestamp":1696522595000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval"],"prefix":"10.1016","volume":"30","author":[{"given":"Diane M.","family":"Donegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Stigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pina","family":"Lardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Mez\u0151si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary N.","family":"Mariash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsteen","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje","family":"Darpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Custodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin L.","family":"Hand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5613-505X","authenticated-orcid":false,"given":"Andreas G.","family":"Moraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eprac.2023.09.011_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2005.08.067","article-title":"Prolonged QTc interval and risk of sudden cardiac death in a population of older adults","volume":"47","author":"Straus","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.eprac.2023.09.011_bib2","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.jacc.2014.08.039","article-title":"The QT interval is associated with incident cardiovascular events: the MESA study","volume":"64","author":"Beinart","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.eprac.2023.09.011_bib3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jacc.2012.01.025","article-title":"Prolongation of QTc and risk of stroke: the REGARDS (REasons for Geographic and Racial Differences in Stroke) study","volume":"59","author":"Soliman","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.011_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","article-title":"Drug- and non-drug-associated QT interval prolongation","volume":"70","author":"van Noord","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.eprac.2023.09.011_bib5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.eprac.2023.09.011_bib6","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3390\/ijms20061324","article-title":"QT assessment in early drug development: the long and the short of it","volume":"20","author":"Lester","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.eprac.2023.09.011_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1573403X10666140514103612","article-title":"The measurement of the QT interval","volume":"10","author":"Postema","year":"2014","journal-title":"Curr Cardiol Rev"},{"issue":"17","key":"10.1016\/j.eprac.2023.09.011_bib10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/0002-9149(92)90904-D","article-title":"Cardiac characteristics and postoperative courses in Cushing's syndrome","volume":"69","author":"Sugihara","year":"1992","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2023.09.011_bib11","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0735-1097(03)00493-5","article-title":"Left ventricular structural and functional characteristics in Cushing's syndrome","volume":"41","author":"Muiesan","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.eprac.2023.09.011_bib12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1507\/endocrj.K09E-198","article-title":"Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing's syndrome","volume":"56","author":"Takagi","year":"2009","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.eprac.2023.09.011_bib13","doi-asserted-by":"crossref","first-page":"E2144","DOI":"10.1210\/jc.2014-1783","article-title":"Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study","volume":"99","author":"Kamenick\u00fd","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2023.09.011_bib14","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1097\/00004872-200110000-00025","article-title":"Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction","volume":"19","author":"Oikarinen","year":"2001","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.eprac.2023.09.011_bib15","first-page":"59","article-title":"QTc and P wave dispersion in patients with Cushing's syndrome","volume":"22","author":"Bayram","year":"2010","journal-title":"Endocr Abstr"},{"issue":"5","key":"10.1016\/j.eprac.2023.09.011_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2265.2011.03975.x","article-title":"Specific electrocardiographic features associated with Cushing's disease","volume":"74","author":"Alexandraki","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2023.09.011_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0031-1271628","article-title":"High prevalence of prolonged QT interval duration in male patients with Cushing's disease","volume":"119","author":"Pecori Giraldi","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"18","key":"10.1016\/j.eprac.2023.09.011_bib18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.109.863209","article-title":"Prevalence of the congenital long-QT syndrome","volume":"120","author":"Schwartz","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2023.09.011_bib19","series-title":"RECORLEV\u00ae (levoketoconazole) [prescribing information]","year":"2021"},{"key":"10.1016\/j.eprac.2023.09.011_bib20","series-title":"ISTURISA\u00ae (osilodrostat) [prescribing information]","year":"2020"},{"key":"10.1016\/j.eprac.2023.09.011_bib21","series-title":"SIGNIFOR\u00ae (pasireotide) injection, for subcutaneous use [prescribing information]","year":"2018"},{"key":"10.1016\/j.eprac.2023.09.011_bib22","series-title":"Inc. SIGNIFOR\u00ae LAR (pasireotide) [prescribing information]","year":"2020"},{"key":"10.1016\/j.eprac.2023.09.011_bib23","series-title":"KORLYM\u00ae (mifepristone) 300 mg tablets [prescribing information]","year":"2019"},{"issue":"4","key":"10.1016\/j.eprac.2023.09.011_bib24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cpdd.389","article-title":"Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study","volume":"7","author":"Hunt","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.eprac.2023.09.011_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.eprac.2023.09.011_bib26","first-page":"401","article-title":"Improving the precision of QT measurements","volume":"18","author":"Darpo","year":"2011","journal-title":"Cardiol J"},{"issue":"10","key":"10.1016\/j.eprac.2023.09.011_bib28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2023.09.011_bib29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/CIRCULATIONAHA.107.728576","article-title":"Cardiovascular effects of noncardiovascular drugs","volume":"120","author":"Raj","year":"2009","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.eprac.2023.09.011_bib30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A\u00a012-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.011_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2023.09.011_bib32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.eprac.2023.09.011_bib33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2023.09.011_bib34","series-title":"Summary of product characteristics: ketoconazole HRA 200 mg tablets","year":"2021"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.011_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2002.tb04419.x","article-title":"Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases","volume":"970","author":"Torpy","year":"2002","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.eprac.2023.09.011_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/nyas.14205","article-title":"Association of hypokalemia with cortisol and ACTH levels in Cushing's disease","volume":"1463","author":"Fan","year":"2020","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.eprac.2023.09.011_bib37","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23005712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23005712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T22:27:39Z","timestamp":1732746459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23005712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1530891X23005712"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.09.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}